Metabolic side effects of antiretroviral therapy;Metabole bijwerkingen van antiretrovirale therapie

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 22, 2008, Pages 1260-1264

  Van Der Valk, M ^a   Reiss, P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATORVASTATIN; CHOLESTEROL; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADIPOSE REDISTRIBUTION SYNDROME; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; METABOLIC DISORDER; MORTALITY; RISK FACTOR; SIDE EFFECT;

ADIPOSE TISSUE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; METABOLIC DISEASES;

EID: 44949237071     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. CBO-richtlijn Antiretrovirale behandeling. Utrecht: Nederlandse Vereniging van Aids Behandelaren; 2007.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
3. Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45:508-14.
4. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-9.
5. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-8.
6. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-5.
7. Fliers E, Sauerwein HP, Romijn JA, Reiss P, Valk M van der, Kalsbeek A, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 2003;362:1758-60.
8. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-70.
9. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-50.
10. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429-38.
11. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-94.
12. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis. 2001;33:1931-7.
13. McComsey GA, Yau L. Asymptomatic hyperlactataemia: predictive value, natural history and correlates. Antivir Ther. 2004;9:205-12.
14. Valk M van der, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093-100.
15. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11-8.
16. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137-44.
17. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813-21.
18. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666-73.
19. Blümer RM, Vonderen MG van, Sutinen J, Hassink E, Ackermans M, Agtmael MA van, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227-36.
20. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-84.
21. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multi-center AIDS cohort study. AIDS. 2005;19:1375-83.
22. Wit S de, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes Care. [ter perse].
23. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-52.
24. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-82.
25. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
26. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
27. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. DAD Study Group. AIDS. 2003;17:1179-93.
28. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. Data Collection Adverse Events of Anti-HIV Drugs (DAD) Study Group. N Engl J Med. 2003;349:1993-2003.
29. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. DAD Study Group. N Engl J Med. 2007;356:1723-35.
30. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. DAD Study Group. Lancet. 2008;371:1417-26.
31. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997;41:898-905.
32. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6:421-5.
33. Valk M van der, Kastelein JJ, Murphy RL, Leth F van, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-14.
34. Leth F van, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19 [onlinetijdschrift].
35. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
36. Gallant JE, Dejesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
37. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med. 2006;355:2283-96.
38. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
39. Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051-8.
40. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. ACTG 5087 Study Team. AIDS Res Hum Retroviruses. 2005;21:757-67.
41. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin. Results of AIDS Clinical Trials Group 5108 Study. AIDS Clinical Trials Group A5108 Team. J Acquir Immune Defic Syndr. 2005;39:307-12.
42. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. NIAID AIDS Clincal Trials Group. AIDS. 2002;16:569-77.
43. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005;19:1103-5.
44. Lee M van der, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, Ven A van der, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127-32.
45. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6:15.